Past rifampicin dosing determines rifabutin resistance of helicobacter pylori

Shoji Suzuki, Hidekazu Suzuki, Toshihiro Nishizawa, Fumihiko Kaneko, Sumire Ootani, Hiroe Muraoka, Yoshimasa Saito, Intetsu Kobayashi, Toshifumi Hibi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Recently, the number of Helicobacter pylori isolates showing antibiotic resistance has been increasing. Rifabutin (RFB) is one of the possible candidates for H. pylori eradication. In the present study, the RFB minimum inhibitory concentrations (MICs) and the resistance-determining genes to RFB (rpoB) were examined to clarify the relationship between drug MICs, rpoB mutations, and past history of rifampicin (RFP) treatment. Methods: The MICs of RFB and rpoB mutations were examined for 48 strains with failure of H. pylori eradication in the University Hospital and 46 isolated from patients at a specialized hospital for chronic respiratory diseases without past H. pylori eradication. Past RFP treatment was also examined. Results: Eight of 94 strains showed high RFB MICs and 6 of the 8 strains showed rpoB point mutations. Although no strains showed high RFB MICs among 48 strains from the patients in the University Hospital, all 7 strains isolated from patients with past RFP treatment showed high RFB MICs (≥0.12 mg/l). Conclusion: Although RFB might be a potential candidate component of a new H. pylori eradication regimen following the first- or second-line failure, it should be used after examining a past history of RFP treatment.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalDigestion
Volume79
Issue number1
DOIs
Publication statusPublished - 2009 Mar

Fingerprint

Rifabutin
Rifampin
Helicobacter pylori
Microbial Sensitivity Tests
Chronic Disease Hospitals
Mutation
Therapeutics
Microbial Drug Resistance
Point Mutation

Keywords

  • Cross-resistance
  • Helicobacter pylori
  • Resistance
  • Rifabutin
  • Rifampicin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Suzuki, S., Suzuki, H., Nishizawa, T., Kaneko, F., Ootani, S., Muraoka, H., ... Hibi, T. (2009). Past rifampicin dosing determines rifabutin resistance of helicobacter pylori. Digestion, 79(1), 1-4. https://doi.org/10.1159/000191204

Past rifampicin dosing determines rifabutin resistance of helicobacter pylori. / Suzuki, Shoji; Suzuki, Hidekazu; Nishizawa, Toshihiro; Kaneko, Fumihiko; Ootani, Sumire; Muraoka, Hiroe; Saito, Yoshimasa; Kobayashi, Intetsu; Hibi, Toshifumi.

In: Digestion, Vol. 79, No. 1, 03.2009, p. 1-4.

Research output: Contribution to journalArticle

Suzuki, S, Suzuki, H, Nishizawa, T, Kaneko, F, Ootani, S, Muraoka, H, Saito, Y, Kobayashi, I & Hibi, T 2009, 'Past rifampicin dosing determines rifabutin resistance of helicobacter pylori', Digestion, vol. 79, no. 1, pp. 1-4. https://doi.org/10.1159/000191204
Suzuki S, Suzuki H, Nishizawa T, Kaneko F, Ootani S, Muraoka H et al. Past rifampicin dosing determines rifabutin resistance of helicobacter pylori. Digestion. 2009 Mar;79(1):1-4. https://doi.org/10.1159/000191204
Suzuki, Shoji ; Suzuki, Hidekazu ; Nishizawa, Toshihiro ; Kaneko, Fumihiko ; Ootani, Sumire ; Muraoka, Hiroe ; Saito, Yoshimasa ; Kobayashi, Intetsu ; Hibi, Toshifumi. / Past rifampicin dosing determines rifabutin resistance of helicobacter pylori. In: Digestion. 2009 ; Vol. 79, No. 1. pp. 1-4.
@article{730cbdabc0f94afc9b8d2a8769864cab,
title = "Past rifampicin dosing determines rifabutin resistance of helicobacter pylori",
abstract = "Background: Recently, the number of Helicobacter pylori isolates showing antibiotic resistance has been increasing. Rifabutin (RFB) is one of the possible candidates for H. pylori eradication. In the present study, the RFB minimum inhibitory concentrations (MICs) and the resistance-determining genes to RFB (rpoB) were examined to clarify the relationship between drug MICs, rpoB mutations, and past history of rifampicin (RFP) treatment. Methods: The MICs of RFB and rpoB mutations were examined for 48 strains with failure of H. pylori eradication in the University Hospital and 46 isolated from patients at a specialized hospital for chronic respiratory diseases without past H. pylori eradication. Past RFP treatment was also examined. Results: Eight of 94 strains showed high RFB MICs and 6 of the 8 strains showed rpoB point mutations. Although no strains showed high RFB MICs among 48 strains from the patients in the University Hospital, all 7 strains isolated from patients with past RFP treatment showed high RFB MICs (≥0.12 mg/l). Conclusion: Although RFB might be a potential candidate component of a new H. pylori eradication regimen following the first- or second-line failure, it should be used after examining a past history of RFP treatment.",
keywords = "Cross-resistance, Helicobacter pylori, Resistance, Rifabutin, Rifampicin",
author = "Shoji Suzuki and Hidekazu Suzuki and Toshihiro Nishizawa and Fumihiko Kaneko and Sumire Ootani and Hiroe Muraoka and Yoshimasa Saito and Intetsu Kobayashi and Toshifumi Hibi",
year = "2009",
month = "3",
doi = "10.1159/000191204",
language = "English",
volume = "79",
pages = "1--4",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Past rifampicin dosing determines rifabutin resistance of helicobacter pylori

AU - Suzuki, Shoji

AU - Suzuki, Hidekazu

AU - Nishizawa, Toshihiro

AU - Kaneko, Fumihiko

AU - Ootani, Sumire

AU - Muraoka, Hiroe

AU - Saito, Yoshimasa

AU - Kobayashi, Intetsu

AU - Hibi, Toshifumi

PY - 2009/3

Y1 - 2009/3

N2 - Background: Recently, the number of Helicobacter pylori isolates showing antibiotic resistance has been increasing. Rifabutin (RFB) is one of the possible candidates for H. pylori eradication. In the present study, the RFB minimum inhibitory concentrations (MICs) and the resistance-determining genes to RFB (rpoB) were examined to clarify the relationship between drug MICs, rpoB mutations, and past history of rifampicin (RFP) treatment. Methods: The MICs of RFB and rpoB mutations were examined for 48 strains with failure of H. pylori eradication in the University Hospital and 46 isolated from patients at a specialized hospital for chronic respiratory diseases without past H. pylori eradication. Past RFP treatment was also examined. Results: Eight of 94 strains showed high RFB MICs and 6 of the 8 strains showed rpoB point mutations. Although no strains showed high RFB MICs among 48 strains from the patients in the University Hospital, all 7 strains isolated from patients with past RFP treatment showed high RFB MICs (≥0.12 mg/l). Conclusion: Although RFB might be a potential candidate component of a new H. pylori eradication regimen following the first- or second-line failure, it should be used after examining a past history of RFP treatment.

AB - Background: Recently, the number of Helicobacter pylori isolates showing antibiotic resistance has been increasing. Rifabutin (RFB) is one of the possible candidates for H. pylori eradication. In the present study, the RFB minimum inhibitory concentrations (MICs) and the resistance-determining genes to RFB (rpoB) were examined to clarify the relationship between drug MICs, rpoB mutations, and past history of rifampicin (RFP) treatment. Methods: The MICs of RFB and rpoB mutations were examined for 48 strains with failure of H. pylori eradication in the University Hospital and 46 isolated from patients at a specialized hospital for chronic respiratory diseases without past H. pylori eradication. Past RFP treatment was also examined. Results: Eight of 94 strains showed high RFB MICs and 6 of the 8 strains showed rpoB point mutations. Although no strains showed high RFB MICs among 48 strains from the patients in the University Hospital, all 7 strains isolated from patients with past RFP treatment showed high RFB MICs (≥0.12 mg/l). Conclusion: Although RFB might be a potential candidate component of a new H. pylori eradication regimen following the first- or second-line failure, it should be used after examining a past history of RFP treatment.

KW - Cross-resistance

KW - Helicobacter pylori

KW - Resistance

KW - Rifabutin

KW - Rifampicin

UR - http://www.scopus.com/inward/record.url?scp=58149399659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149399659&partnerID=8YFLogxK

U2 - 10.1159/000191204

DO - 10.1159/000191204

M3 - Article

C2 - 19142036

AN - SCOPUS:58149399659

VL - 79

SP - 1

EP - 4

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 1

ER -